Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) has approved an increase in the base salary of its Chief Financial Officer, Angela Walsh. According to a statement made in a press release and filed with the Securities and Exchange Commission, the company’s board of directors approved the change on June 27, 2025.
Effective Tuesday, Ms. Walsh’s annual base salary was increased from $279,916 to $321,903. The company said the adjustment followed a review of base salary levels for similar positions among peer companies.
Dogwood Therapeutics is based in Alpharetta, Georgia, and is incorporated in Delaware. The company’s common stock is listed on the Nasdaq Capital Market under the symbol DWTX.
This information is based on a statement from a recent SEC filing.
In other recent news, Dogwood Therapeutics, Inc. reported several significant developments. The company announced that shareholders approved an amendment to its 2020 Equity Incentive Plan, increasing the shares reserved for issuance. Additionally, Dogwood successfully regained compliance with Nasdaq’s minimum stockholders’ equity requirement, reporting a strong cash position of $17.5 million at the end of the first quarter. The company achieved this by executing a Debt Exchange and Cancellation Agreement, which eliminated approximately $19.9 million in debt, and by raising about $4.8 million through the sale of common stock shares. H.C. Wainwright upgraded Dogwood’s stock rating from Neutral to Buy, doubling the price target to $10.00, citing optimism about interim results from the Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain. The Phase 2b study is currently underway, with interim data expected later this year. Dogwood’s research pipeline also includes antiviral programs targeting conditions like fibromyalgia and Long-COVID, with IMC-1 set to enter Phase 3 trials and IMC-2 preparing for Phase 2b trials. These developments reflect Dogwood’s ongoing efforts to advance its clinical programs and strengthen its financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.